芦可替尼保护小鼠移植物抗宿主病中的皮肤干细胞并维持皮肤稳态
该研究在小鼠造血干细胞移植模型中探讨皮肤移植物抗宿主病(GVHD)对Lgr5+毛囊干细胞的影响,发现GVHD导致Lgr5+毛囊干细胞减少并损害毛发再生和伤口愈合,局部外用糖皮质激素虽抗炎但损伤毛囊干细胞且未改善皮肤稳态,而JAK1/2抑制剂芦可替尼显著改善皮肤GVHD、保护Lgr5+毛囊干细胞并恢复毛发再生和伤口愈合。
要点
- GVHD导致小鼠皮肤Lgr5+毛囊干细胞减少,伴毛发再生和伤口愈合受损。
- 局部糖皮质激素虽抗炎但损伤毛囊干细胞,未能改善皮肤稳态。
- 芦可替尼改善皮肤GVHD、保护Lgr5+毛囊干细胞并恢复毛发再生和伤口愈合。
核心结论
- GVHD靶向Lgr5+毛囊干细胞,局部芦可替尼是保护皮肤干细胞并维持GVHD皮肤稳态的新策略。
研究设计与样本
- 研究使用小鼠造血干细胞移植模型,探讨Lgr5+毛囊干细胞在移植后的命运及保护性治疗。
主要发现
- GVHD导致Lgr5+毛囊干细胞减少,并伴有毛发再生和伤口愈合受损。
- 局部糖皮质激素虽具有抗炎作用,但损伤毛囊干细胞且未能改善皮肤稳态。
- JAK1/2抑制剂芦可替尼显著改善皮肤GVHD、保护Lgr5+毛囊干细胞并恢复毛发再生和伤口愈合。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Graft-versus-host disease (GVHD) is the major complication after allogeneic stem cell transplantation (SCT). Emerging evidence indicates that GVHD leads to injury of intestinal stem cells. However, it remains to be investigated whether skin stem cells could be targeted in skin GVHD. Lgr5+ hair follicle stem cells (HFSCs) contribute to folliculogenesis and have a multipotent capacity to regenerate all epithelial cells in repair. We studied the fate of Lgr5+ HFSCs after SCT and explored the novel treatment to protect Lgr5+ HFSCs against GVHD using murine models of SCT. We found that GVHD reduced Lgr5+ HFSCs in association with impaired hair regeneration and wound healing in the skin after SCT. Topical corticosteroids, a standard of care for a wide range of skin disorders including GVHD, damaged HFSCs and failed to improve skin homeostasis, despite of their anti-inflammatory effects. In contrast, JAK1/2 inhibitor ruxolitinib significantly ameliorated skin GVHD, protected Lgr5+ HFSCs, and restored hair regeneration and wound healing after SCT. We, for the first time, found that GVHD targets Lgr5+ HFSCs and that topical ruxolitinib represents a novel strategy to protect skin stem cells and maintain skin homeostasis in GVHD.
引用
- Takahashi S, Hashimoto D, Hayase E, et al. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood. 2018. PMID: 29363542. doi:10.1182/blood-2017-06-792614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。